Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $36.2 million.

  • Xeris Biopharma Holdings' Cash from Financing Activities rose 16786.75% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 65.10%. This contributed to the annual value of $36.2 million for FY2024, which is 2342.28% up from last year.
  • As of FY2024, Xeris Biopharma Holdings' Cash from Financing Activities stood at $36.2 million, which was up 2,342.28% from -$1.6 million recorded in FY2023.
  • Xeris Biopharma Holdings' Cash from Financing Activities' 5-year high stood at $127.5 million during FY2022, with a 5-year trough of -$1.6 million in FY2023.
  • For the 3-year period, Xeris Biopharma Holdings' Cash from Financing Activities averaged around $54.0 million, with its median value being $36.2 million (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Cash from Financing Activities plummeted by 101.27% in 2023 and then skyrocketed by 2,342.28% in 2024.
  • Xeris Biopharma Holdings' Cash from Financing Activities (Yearly) stood at $126.1 million in 2020, then slumped by 78.39% to $27.2 million in 2021, then spiked by 367.84% to $127.5 million in 2022, then crashed by 101.27% to -$1.6 million in 2023, then soared by 2,342.28% to $36.2 million in 2024.